Abstract
Background Dead end 1 (DND1) plays a vital role during oncogenesis and cancer progression by regulating the mRNA content via competitive combination with miRNA, but what function it exerts in prostate cancer has been unclear. The purpose of this paper is to explore the correlation between DND1 expression levels and clinical characteristics in prostate cancer (PCa) patients. Materials and Methods To assess the expression of DND1 in tumor specimens compared with paired paracancerous tissues, the sample from 83 patients was analyzed by immunohistochemistry. The Cancer Genome Atlas (TCGA) database was used to verify our results. Subsequently, we statistically analyzed the relationship between DND1 expression and the clinical prognosis of PCa patients. Results Compared with paracancerous tissues, DND1 has a higher expression level in prostate cancer. The overexpression of DND1 in protein level was significantly associated with the higher clinical stage (P = 0.006), ISUP grading group (P < 0.001), seminal vesicle invasion (P = 0.006), and PSA density (P = 0.002). Furthermore, the overexpression of DND1 indicates a poor clinical prognosis in prostate cancer patients. Conclusion High-level expression of DND1 was associated with tumor progression and poor clinical prognosis. Hence, DND1 may become a potential prognostic biomarker for PCa.
Highlights
Prostate cancer (PCa) is one of the most prevalent solid malignant tumors that threaten men’s health, and the morbidity of prostate cancer ranks the top two among all-male tumors in European countries [1, 2]
To validate the accuracy of our data, The Cancer Genome Atlas (TCGA) database was used to analyze the expression of DND1 mRNA in PCa and normal tissues
The expression of DND1 at the protein level was detected in the prostate targeted biopsy specimen from 83 PCa patients in our institution
Summary
Prostate cancer (PCa) is one of the most prevalent solid malignant tumors that threaten men’s health, and the morbidity of prostate cancer ranks the top two among all-male tumors in European countries [1, 2]. Due to PSA screening and prostate biopsy, an increasing number of prostate cancer patients have been diagnosed [6]. The purpose of this paper is to explore the correlation between DND1 expression levels and clinical characteristics in prostate cancer (PCa) patients. To assess the expression of DND1 in tumor specimens compared with paired paracancerous tissues, the sample from 83 patients was analyzed by immunohistochemistry. We statistically analyzed the relationship between DND1 expression and the clinical prognosis of PCa patients. DND1 has a higher expression level in prostate cancer. The overexpression of DND1 indicates a poor clinical prognosis in prostate cancer patients. High-level expression of DND1 was associated with tumor progression and poor clinical prognosis. DND1 may become a potential prognostic biomarker for PCa
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
